Head-To-Head Comparison: Allurion Technologies (ALUR) versus Its Competitors

Allurion Technologies (NYSE:ALUR) is one of 233 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Allurion Technologies to related businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability.

Risk and Volatility

Allurion Technologies has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500. Comparatively, Allurion Technologies’ rivals have a beta of 0.59, meaning that their average stock price is 41% less volatile than the S&P 500.

Earnings & Valuation

This table compares Allurion Technologies and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Allurion Technologies	$53.47 million	-$80.61 million	-0.28
Allurion Technologies Competitors	$1.04 billion	$3.90 million	-4,409.18

Allurion Technologies’ rivals have higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 48.5% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 20.0% of Allurion Technologies shares are owned by company insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Allurion Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-117.30%	N/A	-85.06%
Allurion Technologies Competitors	-627.86%	-133.35%	-27.87%

Analyst Recommendations

This is a summary of recent ratings for Allurion Technologies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	0	0	2	0	3.00
Allurion Technologies Competitors	1669	4449	8633	232	2.50

Allurion Technologies presently has a consensus price target of $5.00, indicating a potential upside of 362.96%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.05%. Given Allurion Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe Allurion Technologies is more favorable than its rivals.

Summary

Allurion Technologies beats its rivals on 7 of the 13 factors compared.

Allurion Technologies Company Profile

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.